Equities

Hunan Warrant Pharmaceutical Co Ltd

688799:SHH

Hunan Warrant Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)41.90
  • Today's Change1.45 / 3.58%
  • Shares traded2.84m
  • 1 Year change-6.43%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hunan Warrant Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of chemical raw materials, chemical pharmaceutical preparations and traditional Chinese medicine preparations. The Company's products include pharmaceutical preparations, raw materials and intermediates, plant extracts and food. Its products cover areas such as digestion, breathing, and anti-infection. The Company mainly conducts business within the domestic market.

  • Revenue in CNY (TTM)1.45bn
  • Net income in CNY211.45m
  • Incorporated2001
  • Employees1.16k
  • Location
    Hunan Warrant Pharmaceutical Co LtdBuilding C6-C7, Jinrui Lugu ScienceTechnology Park, No. 28 Lutian RoadCHANGSHA 410006ChinaCHN
  • Phone+86 73 185910599
  • Fax+86 73 185910568
  • Websitehttp://www.warrant.com.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hunan Warrant Pharmaceutical Co Ltd1.45bn211.45m3.79bn1.16k17.942.02--2.622.252.2515.4220.060.64261.499.741,244,707.008.3411.219.7914.0561.3269.0012.9813.963.18--0.05668.0510.8418.5015.6019.0224.49--
Obio Technology Shanghai Corp Ltd251.68m-246.61m3.82bn731.00--2.04--15.18-0.3834-0.38340.39152.890.10124.002.55344,293.00-9.930.2246-11.170.2514-26.4236.72-98.161.482.27--0.1040.00-29.6935.88-425.90--57.00--
Beijing Konruns Pharmaceutical Co Ltd846.29m114.79m3.97bn447.0033.921.24--4.690.73110.73115.3820.030.21781.952.901,893,258.003.815.434.486.2487.8389.9317.5220.763.36--0.058221.536.15-2.0848.24-10.6343.05-9.71
Shanghai Fudan Forward S&T Co Ltd638.98m-15.28m3.99bn1.36k--5.17--6.25-0.0222-0.02220.93451.130.37990.64768.53468,807.20-0.9863-0.8781-1.68-1.5336.6343.22-2.60-1.850.413-2.400.3319---13.86-7.58196.17-32.57-13.88--
Data as of Nov 08 2024. Currency figures normalised to Hunan Warrant Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

15.97%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 30 Jun 20241.31m6.56%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024514.89k2.58%
China Southern Asset Management Co., Ltd.as of 30 Jun 2024445.35k2.23%
Essence Fund Co., Ltd.as of 30 Jun 2024325.59k1.63%
Penghua Fund Management Co., Ltd.as of 30 Jun 2024238.11k1.19%
Bosera Asset Management Co., Ltd.as of 30 Jun 2024199.79k1.00%
Great Wall Fund Management Co., Ltd.as of 30 Jun 202496.86k0.49%
Wanjia Asset Management Co., Ltd.as of 30 Jun 202422.52k0.11%
China Nature Asset Management Co., Ltd.as of 30 Jun 202422.00k0.11%
Hui'an Fund Management Co. Ltd.as of 30 Jun 202413.99k0.07%
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.